v3.26.1
Related Party Asset Acquisition of TELI (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Apr. 22, 2026
Mar. 23, 2026
May 19, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Aggregate restricted shares of common stock     333,334          
Cash       $ 5,170,286   $ 5,170,286   $ 7,286,670
Common stock, par value       $ 0   $ 0   $ 0
Deemed dividend       $ 46,113,903 $ 46,113,903  
Bay Shore Trust Warrants [Member]                
Cash $ 1,000,000.0              
Commitment to invest related to clinical milestones $ 4,000,000.0              
Fund commitment, description Under the Funding Commitment, upon the acceptance by the FDA of an Investigational New Drug (IND) application for Telomir-Zn, Bayshore Trust may contribute $2.0 million, in cash or marketable securities valued at the time of transfer, in exchange for 1,492,537 shares of Common Stock, calculated as $2.0 million divided by $1.34, representing the closing trading price of the Common Stock on April 15, 2026. Upon the initiation of a Phase 1/2 clinical study for Telomir-Zn, Bayshore Trust may contribute an additional $2.0 million, in cash or marketable securities valued at the time of transfer, in exchange for an additional 1,492,537 shares of Common Stock (the “Milestone Shares”).              
Contribution amount $ 2,000,000.0              
Exchange of shares 1,492,537              
Bay Shore Trust Warrants [Member] | Investigational New Drug [Member]                
Contribution amount $ 2,000,000.0              
Exchange of shares 1,492,537              
Common stock calculated value $ 2,000,000.0              
Common stock calculated value per share $ 1.34              
Bay Shore Trust [Member]                
Contribution amount $ 1,000,000              
Bay Shore Trust [Member] | Maximum [Member]                
Deemed dividend 46,113,903              
Net increase in shareholders equity $ 1,000,000              
Common Stock [Member]                
Aggregate restricted shares of common stock 34,389,710 34,389,710            
TELI Pharmaceuticals, Inc [Member]                
Percentage of acquire outstanding equity interests 100.00%              
TELI Pharmaceuticals, Inc [Member] | Common Stock [Member]                
Aggregate restricted shares of common stock 34,389,710              
Shares issued value $ 47,113,903              
Common stock, par value $ 1.37              
Historical carrying value $ 0              
TELI Pharmaceuticals, Inc [Member]                
Beneficially owned percentage 1.00%              
TELI Pharmaceuticals, Inc [Member] | Williams [Member]                
Beneficially owned percentage 35.00%              
TELI Pharmaceuticals, Inc [Member] | Aminov [Member]                
Beneficially owned percentage 21.00%              
TELI Pharmaceuticals, Inc [Member] | Mr Aminov [Member]                
Beneficially owned percentage 11.00%              
Beneficially owned percentage 25.00%              
Bay Shore Trust [Member]                
Beneficially owned percentage 14.00%